期刊文献+

GM-CSF+IFN-α诱导CML患者骨髓单个核细胞分化的树突细胞的免疫应答 被引量:3

下载PDF
导出
摘要 目的:为研究临床注射用IFN-α+GM-CSF诱导慢性髓性白血病(CML)患者的骨髓单个核细胞(BMMNC)向树突细胞(DC)的分化及其免疫效应。方法:将取8例CML慢性期患者的BMMNC,接种于用含100 mL/L人AB血清的RMPI1640培养液中,加入不同细胞因子的组合(A组:GM-SCF+IL-4;B组:临床注射用IFN-α+GM-CSF)后进行培养。培养8 d后,在倒置显微镜下观察DC的形态,用流式细胞术检测细胞上的表面标记。采用异基因混合淋巴细胞反应(allo-MLR)检测DC刺激健康供者外周血淋巴细胞增殖的功能,用MTT比色法检测细胞毒性T淋巴细胞(CTL)特异性杀伤白血病细胞的活性。结果:在不同细胞因子组合诱导下分别培养诱导8 d后的DC,其特征性表面标记(CD80、CD86、HLA-DR、CD83、CD1a)的表达率均高于培养前的DC(P<0.05);但培养8 d的两组DC表面标记的表达率无明显差异。allo-MLR在DC与淋巴细胞之比为1∶10时,B组的刺激指数高于A组(P<0.05)。DC能够刺激异体T淋巴细胞产生特异性的CTL。结论:CML患者的BMMNC在GM-CSF+IFN-α诱导下培养后分化的DC可较强地刺激淋巴细胞增殖并可杀伤患者的白血病细胞,有望用于CML的免疫治疗。
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2007年第3期229-231,共3页 Chinese Journal of Cellular and Molecular Immunology
基金 江苏省卫生厅"135"开放课题基金(K0609)
  • 相关文献

参考文献3

  • 1Trombetta ES,Mellman I.Cell biology of antigen processing in vitro and in vivo[J].Annu Rev Immunol,2005,23:975-1028.
  • 2盛立霞,邱国强,谢晓宝,顾伟英,王志林,吴浩清.两种白血病细胞抗原负载DC的体外诱导特异性CTL应答的比较[J].细胞与分子免疫学杂志,2005,21(2):205-209. 被引量:12
  • 3Cortes J,Kantarjian H,O'Brien S,et al.GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia[J].Leukemia,1998,12(6):860-864.

二级参考文献11

  • 1Galea-Lauri J. Immunological weapons against acute myeloid leukaemia[J]. Immunology, 2002, 107(1): 20-27.
  • 2Galea-Lauri J, Darling D, Farzaneh F. A comparison of CTL induction by different methods of antigen loading of monocyte-derived dendritic cells[J]. J Invest Dermatol, 2001, 117: 12.
  • 3Nestle FO. Dendritic cell vaccination for cancer therapy[J]. Oncogene, 2000, 19(56): 6673-6679.
  • 4Galea-Lauri J, Wells JW, Darling D, et al. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination[J]. Cancer Immunol Immunother, 2004, 53(11): 963-977.
  • 5Sallusto F, Cella M, Danieli C, et al. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment-down-regulation by cytokines and bacterial products[J]. J Exp Med, 1995, 182: 389-400.
  • 6Liu Y, Zhang W, Chan T, et al. Engineered fusion hybrid vaccine of IL- 4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity[J]. Leuk Res, 2002, 26(8): 757-763.
  • 7Gottfried E, Krieg R, Eichelberg C, et al. Characterization of cells prepared by dendritic cell-tumor cell fusion[J]. Cancer Immun, 2002, 2: 15.
  • 8Trefzer U, Weingart G, Chen Y, et al. Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma[J]. Int J Cancer, 2000, 85(5): 618-626.
  • 9Kugler A, Stuhler G, Walden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids[J]. Nat Med, 2000, 6(3): 332-336.
  • 10史敦云,李明,卓家才,李玉珠,聂李平,汪明春,张晋萍.脐血造血细胞扩增后细胞成分的变化[J].山西医药杂志,2000,29(6):468-470. 被引量:1

共引文献11

同被引文献23

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部